Drug resistance of mycobacteria: epidemiology
Abstract
Review include the current data on Mycobacterium tuberculosis (MBT) and non-tuberculosis mycobacteria (NTMB) drug resistance mechanisms, on the spread of drug-resistant tuberculosis in world countries and Russian regions (include Moscow), in different age
and social groups, in new and in retreatment cases. Described the drug-resistance spectrum of MBT in world countries and in various spoligotypes, as well as data on drug resistance of fast and slowly growing NTMB, isolated in Moscow.
About the Authors
V. I. Litvinov
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. Yu. Nosova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом
Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
M. V. Makarova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
M. A. Krasnova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
M. V. Sinitsin
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. M. Belilovsky
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. M. Bogorodskaya
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Russian Federation
Russian Federation
References
1. Борисов С.Е., Белиловский Е.М., Данилова И.Д., Рыбка Л.Н. Туберкулез с множественной лекарственной устойчивостью возбудителя / Противотуберкулезная работа в городе Москве. Аналитический обзор статистических показателей по туберкулезу, 2018 г. / Под ред. Е.М. Богородской, В.И. Литвинова, Е.М. Белиловского. – М.: МНПЦБТ, 2019. – Гл. 5. – С. 95-105.
2. Васильева И.А., Белиловский Е.М., Борисов С.Е., Стерликов С.А. Туберкулез с множественной лекарственной устойчивостью возбудителя в странах мира и в Российской Федерации // Туберкулез и болезни легких. – 2017. – Т. 95. – № 11. – С. 5-18.
3. Галкин В.Б., Стерликов С.А., Баласанянц Г.С., Яблонский П.К. Динамика распространенности туберкулеза с множественной лекарственной устойчивостью // Туберкулез и болезни легких. – 2017. – Т. 95. – №. 3. – С. 5-12.
4. Лабораторные исследования при туберкулезе / Под ред. В.И. Литвинова, А.М. Мороза. – М.: МНПЦБТ, 2013. – 342 с.
5. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы // М.: МНПЦБТ. – 2014. – 254 c.
6. Противотуберкулезная работа в городе Москве. Аналитический обзор статистических показателей по туберкулезу, 2018 г./ Под ред. Е.М. Богородской, В.И. Литвинова, Е.М. Белиловского. – М.: МНПЦБТ, 2019. – 216 с.
7. Abubakar I., Laundy M., French C., Shingadia D. Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999-2006 // Arch. Dis. Child. – 2008. – Vol. 93. – N. 12. – P. 1017-1021. doi: 10.1136/adc.2008. 139543.
8. Abubakar I., Dara M., Manissero D. et al. Tackling the spread of drug-resistant tuberculosis in Europe // Lancet. – 2012. – Vol. 379. – P. 21-23.
9. Addo K., Addo S., Mensah G. et al. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana // BMC Infect. Dis. – 2017. – Vol. 17. – N. 1. – P. 743.
10. Ahmed M., Velayati A., Mohammed S. Epidemiology of multidrug-resistant, extensively drug resistant, and totally drug resistant tuberculosis in Middle East countries // Int. J. Mycobacteriol. – 2016. – Vol. 5. – N. 3. – P. 249-256.
11. Akkerman O., Aleksa A., Alffenaar J. et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study // Int. J. Infect. Dis. – 2019. – Vol. 83. – P. 72-76. doi: 10.1016/j.ijid.2019.03.036.
12. Al-Hajoj S., Varghese B., Shoukri M. et al. Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey // Antimicrob. Agents. Chemother. – 2013. – Vol. 57. – N. 5. – P. 2161-2166.
13. Ananta P., Kham-Ngam I., Chetchotisakd P. et al. Analysis of drug-susceptibility patterns and gene sequences associated with clarithromycin and amikacin resistance in serial Mycobacterium abscessus isolates from clinical specimens from Northeast Thailand // PLoS One. – 2018. – Vol. 13. – N. 11. – e0208053.
14. Appelgren A., Morquin D., Dufour S. et al. Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016 // J. Hosp. Infect. – 2017. – Vol. 97. – N. 4. – P. 414-417.
15. Barry P., Gardner T., Funk E. et al. Multistate outbreak of MDR TB identified by genotype cluster investigation // Emerging. Infect. Dis. – 2012. – Vol. 18. – P. 113-116.
16. Becerra M., Lombardía L., Lamas-Maceiras M. et al. Comparative transcriptome analysis of yeast strains carrying slt2, rlm1, and pop2 deletions // Genome. – 2011. – Vol. 54. – N. 2. – P. 99-109. doi: 10.1139/G10-101.
17. Behr M., Falinkham J. Molecular epidemiology of nontuberculous mycobacteria // Future Microbiol. – 2009. – Vol. 4. – P. 1009–1020.
18. Bloom B., Atun R., Cohen T. et al. Tuberculosis //In: Holmes K.K., Bertozzi S., Bloom B.R., Jha P., editors. Major Infectious Diseases. 3rd ed. Chapter 11. – Washington (DC): The International Bank for Reconstruction and Development / The World Bank, 2017.
19. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – Р. 545-582.
20. Cohen T., Murray M., Abubakar I. et al. Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru // Emerging. Infect. Dis. – 2011. – Vol. 17. – P. 969-975.
21. Daley C., Caminero J. Management of multidrug-resistant tuberculosis // Semin. Respir. Crit. Care Med. – 2018. – Vol. 39. – N. 3. – P. 310-324. doi: 10.1055/s-0038-1661383.
22. Dean A., Cox H., Zignol M. Epidemiology of drug-resistant tuberculosis // Adv. Exp. Med. Biol. – 2017. – Vol. 1019. – P. 209-220.
23. Devaux I., Kremer K., Heersma H. et al. Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe // Emerg. Infect. Dis. – 2009. – Vol. 15. – N. 7. – P. 1052-1060.
24. Devaux I., Manissero D., Fernandez de la Hoz K. et al. Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007 // Euro. Surveill. – 2010. – Vol. 15. – N. 11. – pii: 19518.
25. Dheda K., Gumbo T., Gandhi N. et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis // Lancet. Respir. Med. – 2014. – Vol. 2. – N. 4. – P. 321-338.
26. Dheda K., Gumbo T., Maartens G. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis // Lancet. Respir. Med. – 2017. – Vol. 5. – N. 4. – P. 291-360. doi: 10.1016/S2213-2600(17)30079-6.
27. Dheda K., Limberis J., Pietersen E. et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study // Lancet. Respir. Med. – 2017. – Vol. 5. – N. 4. – P. 269-281.
28. Di Gennaro F., Pizzol D., Cebola B. et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review // Tuberculosis (Edinb). – 2017. – Vol. 103. – P. 44-51.
29. Dodd P., Sismanidis C., Seddon J. et al. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study // Lancet. Infect. Dis. – 2016. – Vol. 16. – N. 10. – P. 1193-201.
30. Dymova M., Cherednichenko A, Alkhovik O. et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia // BMC Infect. Dis. – 2014. – Vol. 3. – N. 14. – P. 478.
31. Falzon D., Schünemann H., Harausz E. et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update // Eur. Respir. J. – 2017. – Vol. 49. – N. 3. – pii: 1602308. doi: .1183/13993003.02308-2016.
32. Flores-Treviño S., Mendoza-Olazarán S., Garza-González E. Drug resistance and molecular epidemiology of Mycobacterium tuberculosis in Mexico: a systematic review // Salud. Publica. Mex. – 2014. – Vol. 56. – N. 1. – P. 63-77.
33. Flores-Treviño S., Morfín-Otero R., Rodríguez-Noriega E. et al. Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in Mexico // Enferm. Infect. Microbiol. Clin. – 2015а. – Vol. 33. – N. 3. – P. 181-185.
34. Flores-Treviño S., Morfín-Otero R., Rodríguez-Noriega E. et al. Genetic diversity of Mycobacterium tuberculosis from Guadalajara, Mexico and identification of a rare multidrug resistant Beijing genotype // PLoS One. – 2015b. – Vol. 10. – N. 2. – e0118095.
35. Fox G., Anh N., Nhung N. et al. Latent tuberculous infection in household contacts of multidrug-resistant and newly diagnosed tuberculosis // Int. J. Tuberc. Lung. Dis. – 2017. – Vol. 21. – N. 3. – P. 297-302.
36. Golla V., Snow K., Mandalakas A. et al. The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study // BMC Infect. Dis. – 2017. – Vol. 17. – P. 593.
37. Grandjean L., Iwamoto T., Lithgow A. et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru // PLoS One. – 2015. – Vol. 10. – N. 5. – e0126271.
38. Günther G., van Leth F., Alexandru S. et al. Multidrug-resistant tuberculosis in Europe, 2010-2011 // Emerg. Infect. Dis. – 2015. – Vol. 21. – N. 3. – P. 409-416.
39. Günther G., van Leth F., Alexandru S. et al. Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries // J. Respir. Crit. Care. Med. – 2018. – Vol. 198. – N. 3. – P. 379-386.
40. Haeili M., Darban-Sarokhalil D., Fooladi A. et al. Spoligotyping and drug resistance patterns of Mycobacterium tuberculosis isolates from five provinces of Iran // Microbiologyopen. – 2013. – Vol. 2. – N. 6. – P. 988-996.
41. Hargreaves S., Lönnroth K., Nellums L. et al. Response to Letter to the Editor by M. van der Werf, V. Hollo and C. Ködmön concerning ‘Multidrug-resistant tuberculosis and migration to Europe’ // Clin. Microbiol. Infect. – 2017. – Vol. 23. – N. 8. – P. 580. doi: 10.1016/j.cmi.2017.02.022.
42. Hasan R., Jabeen K., Mehraj V. et al. Trends in Mycobacterium tuberculosis resistance, Pakistan, 1990-2007 // Int. J. Infect. Dis. – 2009. – Vol. 13. – N. 6. – P. 377-382.
43. Hasan R., Jabeen K., Ali A. et al. Extensively drug-resistant tuberculosis, Pakistan // Emerg. Infect. Dis. – 2010. – Vol. 16., - N. 9. – P. 1473-1475.
44. Hashmi H., Javed H., Jamil N. Emerging epidemic of drug resistant tuberculosis in vulnerable populations of developing countries // Afr. Health. Sci. – 2017. – Vol. 17. – N. 2. – P. 599-602.
45. Heidarieh P., Mirsaeidi M., Hashemzadeh M. et al. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran // Microb. Drug. Resist. – 2016. – Vol. 22. – N. 2. – P. 172-178.
46. Hoffner S., Sahebi L., Ansarin K. et al. Mycobacterium tuberculosis of the Beijing genotype in Iran and the World Health Organization Eastern Mediterranean Region: a meta-analysis // Microb. Drug. Resist. – 2018. – Vol. 24. – N. 6. – P. 693-698.
47. Hu Y., Mathema B., Zhao Q. et al. Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China // Clin. Microbiol. Infect. – 2015. – Vol. 21. – N. 12. – P. 1093.
48. Huai P., Huang X., Cheng J. et al. Proportions and risk factors of developing multidrug resistance among patients with tuberculosis in China: a populationbased case-control study // Microb. Drug. Resist. – 2016. – Vol. 22. – N. 8. – P. 717-726.
49. Huo F., Luo J., Shi J. et al. A 10-year comparative analysis shows that increasing prevalence of rifampin-resistant Mycobacterium tuberculosis in China Is associated with the transmission of strains harboring compensatory mutations // Antimicrob. Agents. Chemother. – 2018. – Vol. 27. – P. 62.
50. Jenkins H., Tolman A., Yuen C. et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates // Lancet. – 2014. – Vol. 383. – N. 9928. – P. 1572-1579.
51. Johnston J., Admon A., Ibrahim A. et al. Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a low incidence setting // BMC Infect. Dis. – 2012. – Vol. 12. – P. 266.
52. Kendall E., Fofana M., Dowdy D. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis // Lancet. Respir. Med. – 2015. – Vol. 3. – P. 963-972.
53. Kodama C., Lange B., Olaru I. et al. Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis // Eur. Respir. J. – 2017. – Vol. 26. – P. 50-54.
54. Ködmön C., van den Boom M., Zucs P. et al. Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015 // Euro. Surveill. – 2017. – Vol. 22. – N. 47. doi: 10.2807/1560-7917.ES.2017.22.47.17-00103.
55. Lee M., Sun P., Wu T. et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan // J. Antimicrob. Chemother. – 2017. – Vol. 72. – N. 10. – P. 2782-2786.
56. Lee R., Behr M. The implications of whole-genome sequencing in the control of tuberculosis // Ther. Adv. Infect. Dis. – 2016. - Vol. 3. – N. 2. – P. 47-62. doi: 10.1177/2049936115624630.
57. Liu H., Zhang Y., Liu Z. et al. Associations between Mycobacterium tuberculosis Beijing genotype and drug resistance to four first-line drugs: a survey in China // Front. Med. – 2018. – Vol. 12. – N. 1. – P. 92-97.
58. Loutet M., Davidson J., Brown T. et al. Acquired resistance to antituberculosis drugs in England, Wales, and Northern Ireland, 2000-2015 // Emerg. Infect. Dis. – 2018. – Vol. 24. – N. 3. – P. 524-533.
59. Lowenthal P., Lin S., Desmond E. et al. Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis //Clin. Infect. Dis. – 2019. – Vol. 69. – N. 4. – P. 668-675. https://doi.org/10.1093/cid/ciy937.
60. Lu P., Ding X., Liu Q. et al. Mediating effect of repeated tuberculosis exposure on the risk of transmission to household contacts of multidrug-resistant tuberculosis patients // Am. J. Trop. Med. Hyg. – 2018. – Vol. 98. – N. 2. – P. 364-371.
61. Luo L., Li B., Chu H. et al. Characterization of Mycobacterium Abscessus subtypes in Shanghai of China: drug sensitivity and bacterial epidemicity as well as clinical manifestations // Medicine (Baltimore). – 2016. – Vol. 95. – N. 3. – e2338.
62. McBryde E., Meehan M., Doan T. et al. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains // Int. J. Infect. Dis. – 2017. – Vol. 56. – P. 14-20.
63. Manfredi R., Nanetti A., Morelli S. et al. A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection // HIV Clin. Trials. – 2004a. – Vol. 5. – N. 4. – P. 206-215.
64. Manfredi R., Nanetti A., Valentini R. et al. Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study // HIV Med. – 2004b. – Vol. 5. – N. 6. – P. 431-436.
65. Manson A., Cohen K., Abeel T. et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance // Nat. Genet. – 2017. – Vol. 49. – N. 3. – P. 395-402.
66. Matteelli A., Centis R., D’Ambrosio L. et al. WHO strategies for the programmatic management of drug-resistant tuberculosis // Expert. Rev. Respir. Med. – 2016. – Vol. 10. – N. 9. – P. 991-1002. doi: 10.1080/17476348.2016.1199278.
67. Mesfin Y., Hailemariam D., Biadglign S. et al. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis // PLoS One. – 2014. – Vol. 9. – e82235.
68. Murase Y., Maeda S., Yamada H. et al. Clonal expansion of multidrug-resistant and extensively drug-resistant tuberculosis, Japan // Emerg. Infect. Dis. – 2010. – Vol. 16. – N. 6. – P. 948-954.
69. Nellums LB, Thompson H, Holmes A, et al. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis // Lancet. Infect. Dis. – 2018. – Vol. 18. – N. 7. – P. 796-811.
70. Nodieva A., Jansone I., Broka L. et al. Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis // Int. J. Tuberc. Lung. Dis. – 2010. – Vol. 14. – P. 427-433.
71. Outhred A., Britton P., Marais B. Drug-Resistant tuberculosis – primary transmission and management // J. Infect. – 2017. – Vol. 74. – P. 128-135.
72. Palmero D., Cusmano L., Bucci Z. et al. Infectiousness and virulence of multidrug-resistant and drug susceptible tuberculosis in adult contacts // Medicina (B Aires). – 2002. – Vol. 62. – N. 3. – P. 221-225.
73. Pang Y., Xia H., Zhang Z. et al. Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis // J. Clin. Microbiol. – 2013. – Vol. 51. – N. 6. – P. 1707-1713.
74. Rendon A., Centis R., D’Ambrosio L., Migliori G. WHO strategies for the management of drug-resistant tuberculosis // Arch. Bronconeumol. – 2017. – Vol. 53. – N. 3. – P. 95-97. doi: 10.1016/j.arbres.2016.07.015.
75. Rumende C. Risk factors for multidrug-resistant tuberculosis // Acta. Med. Indones. – 2018. – Vol. 50. – N. 1. – P. 1-2.
76. Sahebi L., Ansarin K., Hoffner S. et al. Molecular epidemiology of Mycobacterium tuberculosis strains in the North-West and West of Iran // Ann. Med. Health. Sci. Res. – 2015. – Vol. 5. – N. 5. – P. 334-339.
77. Seaworth B., Griffith D. therapy of multidrug-resistant and extensively drug-resistant tuberculosis // Microbiol. Spectr. – 2017. – Vol. 5. – N. 2. doi: 10.1128/microbiolspec.
78. Seddon J., Hesseling A., Marais B. et al. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa // Int. J. Tuberc. Lung. Dis. – 2012a. – Vol. 16. – N. 7. – P. 928-933.
79. Seddon J., Jordaan A., Victor T. et al. Discordant drug susceptibility for mycobacterium tuberculosis within families // Pediatr. Infect. Dis. J. – 2012b. – Vol. 31. – N. 7. – P. 783-785.
80. Seddon J., Warren R., Enarson D. et al. Drug-resistant tuberculosis transmission and resistance amplification within families // Emerg. Infect. Dis. – 2012c. – Vol. 18. – N. 8. – P. 1342-1345.
81. Seddon J., Hesseling A., Godfrey-Faussett P. et al. Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study // BMC Infect. Dis. – 2013. – Vol. 13. - P. 392.
82. Shah I. Multidrug-resistant tuberculosis in children from 2003 to 2005: a brief report // Indian. J. Med. Microbiol. – 2012. – Vol. 30. – N. 2. – P. 208-211.
83. Shah N., Yuen C., Heo M. et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis // Clin. Infect. Dis. – 2014. – Vol. 58. – N. 3. – P. 381-391.
84. Shah N., Auld S., Brust J. et al. transmission of extensively drug-resistant tuberculosis in South Africa // N. Engl. J. Med. – 2017. – Vol. 376. – N. 3. – P. 243-253.
85. Shiau M., Lee M., Huang T. et al. Mycobacterial prevalence and antibiotic resistance frequency trends in Taiwan of mycobacterial clinical isolates from 2002 to 2014 // Medicine (Baltimore). – 2016. – Vol. 95. – N. 12. – e2942.
86. Shitrit D., Baum G., Priess R. et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome // Chest. – 2006. – Vol. 129. – N. 3. – P. 771-776.
87. Smith S., Pratt R., Trieu L. et al. Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014 // Clin. Infect. Dis. – 2017. – Vol. 65. – N. 9. – P. 1437-1443.
88. Sotgiu G., D’Ambrosio L., Centis R. et al. TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel? // Eur. Respir. J. – 2011. – Vol. 38. – P. 1221-1223.
89. Sotgiu G., Tiberi S., D’Ambrosio L. et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis // Lancet. – 2016. – Vol. 387. – N. 10037. – P. 2486-2487. doi: 10.1016/S0140-6736(16)30729-2.
90. Tanasescu M., Didilescu C., Marica C. Present and future perspectives for the rapid molecular diagnosis of TB and MDR-TB // Pneumologia. – 2013. – Vol. 62. – N. 4. – P. 198-205.
91. Tanveer M., Hasan Z., Siddiqui A. et al. Genotyping and drug resistance patterns of M. tuberculosis strains in Pakistan // BMC Infect. Dis. – 2008. – Vol. 24. – N. 8. – P. 171.
92. Tarashi S., Fateh A., Jamnani F. et al. Prevalence of Beijing and Haarlem genotypes among multidrug-resistant Mycobacterium tuberculosis in Iran: Systematic review and meta-analysis // Tuberculosis (Edinb). – 2017. – Vol. 107. – P. 31-37.
93. Teixeira L., Perkins M., Johnson J. et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis // Int. J. Tuberc. Lung. Dis. – 2001. – Vol. 5. – P. 321-328.
94. van den Hof S., Tursynbayeva A., Abildaev T. et al. HIV and multidrug-resistant tuberculosis: overlapping risk factors // Eur. Respir. J. – 2015. – Vol. 45. – P. 567-569.
95. van Ingen J., Boeree M., Wright A. et al. Second-line drug resistance in multidrug-resistant tuberculosis cases of various origins in the Netherlands // Int. J. Tuberc. Lung. Dis. – 2008. – Vol. 12. – N. 11. – P. 1295-1299.
96. van Ingen J., Boeree M., van Soolingen D., Mouton J. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria // Drug. Resist. Updat. – 2012. – Vol. 15. – N. 3. – P. 149-161.
97. Walker T., Merker M., Knoblauch A. et al. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study // Lancet. Infect. Dis. – 2018. – Vol. 18. – N. 4. – P. 431-440.
98. WHO Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control // Wkly. Epidemiol. Rec. – 2006. – Vol. 81. –Р. 430-432.
99. World Health Organization (WHO). Tuberculosis MDR-TB and XDR-TB 2011 progress report. [Электронный ресурс]. URL: http://www.who.int/tb/challenges/mdr/factsheet _mdr_progress_march2011.pdf. (Дата обращения 12.09.2019).
100. World Health Organization (WHO). Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. – Geneva:
101. WHO, 2014. [Электронный ресурс]. URL: http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf?ua=1. (Дата обращения 12.09.2019).
102. World Health Organization (2014a). Drug-resistant TB – surveillance and response. Supplement to global tuberculosis report 2014. WHO/HQ/TB/ 2014.12. – Geneva: WHO, 2014. [Электронный ресурс]. URL: https://www.who.int/tb/publications/global_report/gtbr14_supplement_web_v3.pdf. (Дата обращения 12.09.2019).
103. World Health Organization (2014b). Xpert MTB/RIF implementation manual. Technical and operational “how-to”: practical considerations. – Geneva: WHO, 2014. [Электронный ресурс]. URL: https://apps.who.int/iris/bitstream/handle/10665/112469/9789241506700_eng.pdf?sequence=1. (Дата обращения 12.09.2019).
104. World Health Organization (2016) Global tuberculosis report 2015. – Geneva: WHO, 2016.
105. [Электронный ресурс]. URL: http://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf. (Дата обращения 12.09.2019).
106. Zhang J., Gou H., Hu X. et al. Status of drug-resistant tuberculosis in China: A systematic review and meta-analysis // Am. J. Infect. Control. – 2016. – Vol. 44. – N. 6. – P. 671-676.
107. Zhang Z., Pang Y., Wang Y. et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China // Int. J. Antimicrob. Agents. – 2015. – Vol. 45. – N. 5. – P. 491-495.
108. Zhao X., Wang Y., Pang Y. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China // Methods. Mol. Biol. – 2015. – Vol. 1285. – P. 281-292.
109. Zignol M., Dara M., Dean A., et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data // Drug. Resist. Updat. – 2013a. – Vol. 16. – N. 6. – P. 108-115.
110. Zignol M., Sismanidis C., Falzon D. et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance // Eur. Respir. J. – 2013b. – Vol. 42. – N. 3. – P. 701-707. doi: 10.1183/09031936.00175812
111. Zürcher K., Ballif M., Fenner L. et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. International epidemiology databases to evaluate AIDS (IeDEA) consortium // Lancet Infect. Dis. – 2019. – Vol. 19. – N. 3. – P. 298-307
Review
For citations:
Litvinov V.I., Nosova E.Yu., Makarova M.V., Krasnova M.A., Sinitsin M.V., Belilovsky E.M., Bogorodskaya E.M. Drug resistance of mycobacteria: epidemiology. Tuberculosis and socially significant diseases. 2019;(3):42-66. (In Russ.)
Views:
37
Email this article 